Sylvest Advisors’s AbbVie ABBV Stock Holding History

Sylvest Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,704	Closed	-$1.3M	–	71
2025 Q4	$1.3M	Sell	5,704 -550	-9%	-$125K	0.7%	16
2025 Q3	$1.45M	Sell	6,254 -250	-4%	-$50.9K	0.78%	15
2025 Q2	$1.21M	Buy	6,504 +230	+4%	+$42.7K	0.7%	16
2025 Q1	$1.31M	Sell	6,274 -139	-2%	-$27K	0.82%	15
2024 Q4	$1.14M	Buy	+6,413	New	+$1.18M	0.7%	20

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sylvest Advisors's ABBV Position: Q1 2026 in Review

Sylvest Advisors sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 5,704 shares — an estimated $1.3M sold.

Sylvest Advisors first reported a position in ABBV in Q4 2024 and held it in 5 quarters. The position peaked at $1.45M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Sylvest Advisors reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Sylvest Advisors sold 5,704 AbbVie shares in Q1 2026, an estimated $1.3M.
Sylvest Advisors first reported a position in AbbVie in Q4 2024 and held it in 5 quarters.
Sylvest Advisors's AbbVie position peaked at $1.45M in Q3 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sylvest Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.